MCM
SLXP

Manchester Capital Management’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Manchester Capital Management’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-3,242
Closed -$292K – 1019
2013
Q4 		$292K Sell
3,242
-2,088
-39% -$167K 0.05% 250
2013
Q3 		$356K Hold
5,330
– – 0.06% 200
2013
Q2 		$353K Buy
+5,330
New +$305K 0.07% 181

Other funds holding SLXP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Manchester Capital Management's SLXP Position: Q1 2014 in Review

Manchester Capital Management sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2014, closing a stake of 3,242 shares — an estimated $292K sold.

Manchester Capital Management first reported a position in SLXP in Q2 2013 and held it in 3 quarters. The position peaked at $356K in Q3 2013. 304 funds tracked by Wall St. Rank hold SLXP as of Q1 2014.

  • Manchester Capital Management reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2014 after selling out during the quarter.
  • Manchester Capital Management sold 3,242 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2014, an estimated $292K.
  • Manchester Capital Management first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 3 quarters.
  • Manchester Capital Management's SALIX PHARMACEUTICALS LTD DEL position peaked at $356K in Q3 2013.
  • 304 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2014.

Based on Manchester Capital Management's 13F filing for Q1 2014, filed 2 May 2014.